How to Use QUEST Moxidectin Safely in Horses

By Dr Duncan Houston

QUEST® is one of the most useful equine dewormers available, but it is also one of the products that should be used most deliberately.

Moxidectin can treat adult small strongyles and certain encysted larval stages that most routine dewormers do not adequately target. However, it does not eliminate every encysted larva, it does not treat tapeworms unless combined with praziquantel, and it should not simply be given to every horse according to a fixed calendar.

The mistake I see most often is treating the product as either dangerously strong or magically comprehensive. Neither is accurate. Used at the correct dose in an appropriate horse, moxidectin is generally safe and effective. Used carelessly, particularly in a small, young, underweight or debilitated horse, it can cause serious neurological toxicity.

Quick Answer

QUEST® contains moxidectin, a macrocyclic lactone dewormer that treats many adult and larval equine parasites, including certain encysted small strongyle larvae.

Under the current US label, it is intended for horses and ponies at least six months old and is dosed at 0.4 mg/kg according to current body weight. Do not use it in sick, debilitated or underweight horses without veterinary direction, and use extreme care when dosing foals, young horses, ponies and miniature horses.

QUEST® does not treat tapeworms. QUEST® PLUS contains both moxidectin and praziquantel for tapeworm control. Current guidelines also recommend against using moxidectin as a routine interval treatment without considering age, parasite risk, faecal testing, local resistance and pasture conditions.

What Is QUEST Moxidectin?

QUEST® Gel is a 2 percent equine oral gel containing 20 mg of moxidectin per mL. Moxidectin belongs to the macrocyclic lactone family, the same broad drug class as ivermectin.

It interferes with chloride-channel-mediated nerve transmission in susceptible parasites. This produces paralysis and eventual elimination of the parasite.

The current US product is labelled for oral use in horses and ponies six months of age and older. The label includes breeding mares and stallions when the product is used as directed.

Product names, syringe sizes, legal classifications and age restrictions differ between countries. This article refers primarily to the US QUEST® label. Always follow the label supplied with the product sold in your country and any directions from your veterinarian or authorised prescriber.

What Parasites Does QUEST Treat?

The US QUEST® label includes activity against several gastrointestinal parasites and some migrating stages.

Parasite group	Important labelled stages
Small strongyles	Adults, undifferentiated lumenal larvae and encysted late L3 and L4 mucosal larvae
Large strongyles	Adults and certain arterial or tissue stages, depending on the species
Ascarids	Adults and L4 larvae
Pinworms	Adults and L4 larvae
Hairworms	Adults
Large-mouth stomach worms	Adults
Bots	Specified second and third instars
Tapeworms	Not treated by standard QUEST® Gel

The exact species and stages are listed on the product label. A label claim does not guarantee that every parasite population on every property remains susceptible, which is why post-treatment efficacy monitoring matters.

Does QUEST Treat Tapeworms?

Standard QUEST® Gel does not contain praziquantel and does not treat tapeworms.

QUEST® PLUS contains:

• Moxidectin for susceptible nematodes and bots

• Praziquantel for adult Anoplocephala perfoliata tapeworms

The two products should not be treated as interchangeable. If tapeworm treatment is indicated, confirm that the product actually contains praziquantel rather than assuming every moxidectin syringe covers tapeworms.

This distinction matters because a horse can receive an effective moxidectin treatment against strongyles and still retain a tapeworm burden if praziquantel was not included.

What Are Encysted Small Strongyles?

Small strongyles, also called cyathostomins or small redworms, are among the most common gastrointestinal parasites found in grazing horses.

Horses ingest infective larvae from contaminated pasture. After entering the large intestine, some larvae penetrate the intestinal lining and continue developing within the mucosa. Others may remain inhibited or encysted for extended periods before returning to the intestinal lumen and maturing into adults.

Most grazing horses are exposed, and most infections do not produce obvious disease. The major concern is a much less common syndrome called larval cyathostominosis, in which large numbers of larvae emerge from the intestinal lining and produce severe inflammation of the caecum and colon.

Signs of larval cyathostominosis can include:

• Acute or persistent diarrhoea

• Weight loss

• Colic

• Reduced appetite

• Dehydration

• Low blood protein

• Swelling beneath the abdomen or limbs

• Fever or marked lethargy

• Thickening of the large intestinal wall on ultrasound

Young horses, particularly those under five years old, are generally at greater risk of carrying substantial larval burdens. Geriatric horses and horses with PPID may also warrant closer monitoring.

Does Moxidectin Kill All Encysted Small Strongyles?

No.

QUEST® has a label claim against encysted late L3 and L4 mucosal cyathostome larvae, which makes it different from ivermectin. However, no currently available dewormer should be expected to eliminate every encysted larva.

The 2024 AAEP guidelines report that moxidectin’s efficacy against developing encysted larvae has commonly been in the approximate 50 to 70 percent range. In one controlled study, moxidectin reduced early L3 larvae by about 74 percent and late L3 or L4 larvae by about 75 percent two weeks after treatment. Its reduction of lumenal worms was considerably higher.

The practical interpretation is:

• Moxidectin has useful larvicidal activity

• It is not a complete intestinal clean-out

• Some larvae will survive treatment

• Larval numbers can increase again after treatment

• Repeated treatment should not be used in an attempt to eradicate all parasites

The objective of parasite control is to prevent disease and reduce transmission while preserving drug effectiveness, not to make the horse permanently parasite-free.

Is Moxidectin Better Than a Five-Day Fenbendazole Treatment?

Moxidectin and a five-day fenbendazole regimen are the two commonly recognised treatments with registered activity against encysted cyathostomin larvae.

However, the idea that a five-day fenbendazole course is always a reliable substitute is outdated.

Current AAEP guidance notes that:

• Both treatments may achieve less than 85 percent larval reduction

• Fenbendazole larvicidal efficacy has declined substantially from historical levels

• Benzimidazole resistance is widespread

• Moxidectin generally retains much better activity against adult cyathostomins in the intestinal lumen

• The overall reduction in the cyathostomin population is therefore generally greater after effective moxidectin treatment

A five-day fenbendazole course should not be assumed to work simply because it is longer or requires more paste. Its efficacy should be evaluated on the individual property.

Can a Faecal Egg Count Detect Encysted Larvae?

No.

A standard faecal egg count measures eggs produced by sexually mature female worms within the intestinal lumen. Encysted larvae do not produce eggs.

A low or zero strongyle faecal egg count therefore does not prove that the horse has no encysted cyathostomins.

Faecal egg counts are useful for:

• Estimating how many strongyle eggs an adult horse is shedding

• Identifying horses contributing heavily to pasture contamination

• Monitoring the presence of ascarid eggs in young horses

• Conducting a faecal egg count reduction test after treatment

• Monitoring how quickly strongyle eggs reappear after treatment

They are not reliable for:

• Measuring the total number of worms inside an individual horse

• Detecting encysted larvae

• Diagnosing larval cyathostominosis

• Predicting whether a horse will react adversely to treatment

• Proving that parasites are causing weight loss, diarrhoea or colic

This is why choosing moxidectin involves more than looking at one egg count. Age, grazing history, previous treatments, pasture contamination, clinical history and local parasite epidemiology all matter.

When Should Moxidectin Be Used?

There is no universal month when every horse should receive moxidectin.

Moxidectin may be considered when:

• Control of susceptible adult small strongyles is required

• Activity against certain encysted larval stages is considered appropriate

• The horse is old enough and in suitable health

• Moxidectin remains effective on the property

• The treatment fits the local transmission season

• The horse’s previous deworming history supports its use

• A veterinarian or prescriber considers larvicidal treatment justified

• A broader baseline treatment is required under the regional control plan

Current guidelines agree that fixed interval treatment of every horse throughout the year should be abandoned. They differ somewhat in their exact treatment frameworks because climate, parasite prevalence, diagnostic access and regulatory systems vary between countries.

Current US approach

The AAEP recommends that most mature horses receive one or two baseline macrocyclic lactone treatments per year, with additional strongyle treatments directed mainly towards high egg-shedding horses and timed during active parasite transmission.

That does not mean both baseline treatments must be moxidectin. Ivermectin and moxidectin each have advantages and limitations, and the choice should reflect the parasites being targeted.

Current UK risk-based approach

The 2026 CANTER guidance states that blanket autumn or winter larvicidal treatment of every horse is not considered necessary. Larvicidal treatment should instead be focused on horses whose age, history, pasture exposure and test results suggest an increased risk.

The strongest shared message is this:

Use moxidectin because there is a reason to use it, not because the calendar says the tube is due.

Should Every Horse Receive Moxidectin in Autumn?

No.

In temperate climates, encysted cyathostomin larvae may be more abundant during autumn and winter, which historically led to routine late-season larvicidal treatment.

However, current guidance does not support automatically treating every horse with moxidectin each autumn.

The decision should consider:

• The horse’s age

• Previous high or low strongyle egg shedding

• Whether the horse grazes contaminated pasture

• Stocking density

• Manure removal

• Regional transmission patterns

• Previous larval cyathostominosis on the property

• Whether moxidectin remains effective

• Whether tapeworm treatment is also required

• Whether the horse is underweight, unwell or otherwise unsuitable

CANTER notes that evidence has not established that blanket autumn or winter larvicidal treatment reduces the risk of clinical larval cyathostominosis. Unnecessary treatment also increases resistance selection pressure.

What Does the 84-Day Claim Mean?

The current US QUEST® label states that one treatment suppresses strongyle egg production for 84 days. That claim arose from the studies supporting the original product approval.

However, field performance has changed.

The egg reappearance period is the time between effective treatment and the return of strongyle egg shedding. Historically, moxidectin egg reappearance periods were commonly reported at 12 to 16 weeks. Several more recent studies have reported egg reappearance after only four to five weeks, particularly in young horses and some managed populations.

This does not mean every horse begins shedding again at four weeks, and a shortened egg reappearance period does not automatically prove conventional resistance. Some properties still report substantially longer suppression.

It does mean that owners should not assume one moxidectin treatment will suppress egg shedding for exactly 12 weeks on every farm.

Importantly, shortened egg suppression does not justify simply treating more frequently. It should prompt:

• Review of the deworming programme

• Better pasture hygiene

• An efficacy check

• Monitoring of egg reappearance

• Reduction of unnecessary treatments

• Veterinary or parasitology advice

Is QUEST Safe for Horses?

When used according to the label in a suitable horse, moxidectin is generally well tolerated.

The US label permits use in horses and ponies six months of age and older. It also reports reproductive safety in breeding mares and stallions when used as directed.

However, the label contains important warnings:

• Use extreme caution in foals, young horses and miniature horses

• Do not overdose

• Do not use in sick horses

• Do not use in debilitated horses

• Do not use in underweight horses

• Do not use the equine product in another animal species

Transient depression, incoordination, ataxia or recumbency may occur, particularly when very young or debilitated animals are treated. Supportive veterinary care may be required.

Why Are Ponies, Minis and Underweight Horses at Greater Risk?

The principal practical problem is dosing error.

A full syringe intended to treat a large horse can deliver several times the correct dose to a pony, miniature horse or foal. Even a smaller error becomes proportionally more important as body weight decreases.

Owners also commonly underestimate or guess body weight, use an old weight measurement or assume that every adult-looking equid weighs roughly 500 kg.

For moxidectin, that is not good enough.

The horse should be weighed using:

1. A calibrated equine scale where available

2. A correctly used equine weight tape

3. A validated body measurement formula when neither is available

A scale is preferable for miniature horses, ponies, youngstock and horses with unusual body proportions because weight tapes may be less accurate in these animals.

Can QUEST Be Used in Foals?

Under the current US label, QUEST® is for horses and ponies six months of age and older.

Do not use it in a younger foal simply by calculating a smaller amount.

Young foals are particularly vulnerable to moxidectin overdose, and reported toxicity has included severe depression, weakness, ataxia, breathing abnormalities, tremors, seizures and coma.

There is another important reason not to reach automatically for moxidectin in young horses: Parascaris resistance to macrocyclic lactones is widespread.

For young foals, current parasite-control programmes usually target ascarids initially with an effective benzimidazole or, where known to be effective, pyrantel. The choice should be informed by age, local resistance and faecal testing as the foal grows.

The presence of an ascarid label claim does not guarantee that moxidectin will be effective against the ascarid population on a particular breeding property.

Can QUEST Be Used in Senior Horses?

Age alone does not prohibit moxidectin use, but senior horses require a closer assessment before treatment.

Check:

• Current body condition

• Muscle loss

• Dental disease

• Hydration

• Appetite

• Chronic diarrhoea

• Liver or kidney disease

• PPID status

• Current medications

• Previous reactions

• Ability to swallow normally

Some senior horses and horses with PPID may become higher strongyle egg shedders, but that does not mean an underweight or debilitated senior should automatically receive moxidectin.

A thin senior horse with diarrhoea or weight loss needs a veterinary examination, not a reflex dose of a potent dewormer in the hope that parasites are the sole explanation.

What Is the Correct Dose?

The labelled dose is:

0.4 mg of moxidectin per kg of body weight

This is equivalent to 400 micrograms/kg.

The current US QUEST® syringe is calibrated in 50 lb increments and contains enough gel to treat a total body weight of up to 1,500 lb. Product presentations in other countries may use different syringe sizes and graduations.

The safest process is:

1. Confirm the exact product.

2. Confirm whether it is moxidectin alone or moxidectin with praziquantel.

3. Check the expiry date and storage history.

4. Obtain a current body-weight estimate.

5. Read the syringe increments carefully.

6. Set the dose ring before approaching the horse.

7. Recheck the setting.

8. Ensure the horse’s mouth is free from feed.

9. Deposit the gel towards the back of the tongue.

10. Watch the horse swallow.

Do not dose several horses while distracted, rushing or trying to remember each animal’s weight from last season.

Why Is Underdosing Also a Problem?

Most warnings focus on overdose, but deliberate underdosing is not safe parasite management.

Underdosing can:

• Produce inadequate parasite removal

• Leave adult worms continuing to shed eggs

• Increase selection pressure for drug resistance

• Create false confidence that treatment has been completed

• Complicate interpretation of a later efficacy test

The label specifically instructs owners not to underdose and to use a current body weight.

The goal is not to give the smallest amount you hope will work. The goal is to administer the labelled dose accurately.

What If the Horse Spits Some of the Gel Out?

Do not automatically administer another complete dose.

It may be impossible to determine exactly how much was swallowed. Giving the full dose again could result in a substantial overdose.

Instead:

• Photograph or estimate the amount lost

• Keep the syringe and packaging

• Record the horse’s weight and original dose setting

• Contact your veterinarian or the product manufacturer

• Follow the advice given for that individual situation

• Consider an appropriately timed efficacy check if treatment success is uncertain

A tiny smear on the lips is different from most of the dose landing on the floor. The response should be proportional to what actually happened.

QUEST, QUEST PLUS, Ivermectin or Fenbendazole?

Product or drug	Main advantage	Major limitation
QUEST® moxidectin	Broad nematode activity with labelled activity against certain encysted cyathostomin larvae	No tapeworm treatment; accurate dosing is essential
QUEST® PLUS	Moxidectin activity plus praziquantel for tapeworms	Same moxidectin precautions; combination should be used only when both components are indicated
Ivermectin	Broad activity against susceptible adult and migrating parasites and useful bot activity	No registered efficacy against encysted cyathostomin larvae
Five-day fenbendazole	Registered larvicidal regimen	Widespread resistance and substantially reduced efficacy on many properties
Pyrantel	May be useful where susceptible and has a tapeworm dose option in some regions	Does not treat encysted larvae; resistance is common in cyathostomins

No product is automatically best for every treatment. The correct choice depends on the parasite, horse, age group, location and known efficacy on the property.

What Should You Expect After Giving Moxidectin?

Most healthy horses receiving the correct labelled dose should show no obvious adverse effects.

Continue routine observation, particularly during the first 24 hours.

Monitor:

• Appetite

• Alertness

• Coordination

• Ability to walk normally

• Manure

• Signs of colic

• Facial or muzzle swelling

• Muscle tremors

• Ability to stand

• Breathing

Very rare adverse effects described in authorised moxidectin product information include depression, ataxia, abdominal discomfort, tremors, a flaccid lower lip and muzzle swelling. Mild transient colic or loose manure may occasionally occur in horses carrying very high parasite burdens.

A mild change should still be discussed with your veterinarian if it persists, worsens or involves coordination.

How Serious Is a Dosing Error?

Low Risk

The horse:

• Is a healthy adult

• Was weighed appropriately

• Received the correct dose

• Swallowed normally

• Remains bright and coordinated

What to do: Continue normal observation. Record the treatment, product, dose and batch details.

Moderate Risk

There is:

• Uncertainty about the horse’s weight

• A small dosing discrepancy

• Partial loss of the gel

• A mild reduction in appetite

• Mild dullness without incoordination

• Treatment of a small pony close to the calculated setting

What to do: Contact your veterinarian or the manufacturer for individual advice. Monitor closely for at least 24 hours and do not administer more product unless instructed.

High Risk

The horse:

• Received substantially more than the calculated dose

• Is young, miniature, underweight or debilitated

• Develops marked depression

• Appears weak or unsteady

• Shows muscle tremors

• Has difficulty eating

• Develops colic or persistent diarrhoea

What to do: Contact an equine veterinarian immediately. Keep the horse in a quiet, safe area and prevent falls.

Critical

The horse:

• Becomes recumbent

• Cannot stand

• Develops severe ataxia

• Has abnormal or difficult breathing

• Has seizures

• Becomes minimally responsive or comatose

• Is rapidly deteriorating

What to do: Treat this as an emergency. Veterinary supportive care may be required for an extended period.

When Is This an Emergency?

Contact an equine veterinarian immediately after moxidectin administration if the horse develops:

• Severe weakness

• Marked incoordination

• Repeated falling

• Recumbency

• Tremors or seizures

• Difficulty breathing

• Profound depression

• Inability to swallow

• Severe or persistent colic

• Severe diarrhoea

• Collapse

• An accidental major overdose

Reported overdose signs have appeared within approximately 6 to 22 hours and have sometimes persisted for several days. Young foals were overrepresented in published toxicity reports. There is no specific antidote, so treatment is based on supportive care, monitoring, fluid therapy and management of complications. (Mad Barn USA)

Do not wait for the horse to become recumbent before seeking advice when a significant overdose is known to have occurred.

What Should You Do After an Accidental Overdose?

1. Call an equine veterinarian immediately.

2. Keep the syringe and packaging.

3. Record the product, concentration, amount given and time administered.

4. Provide the horse’s current weight, age and health status.

5. Move the horse only if this can be done safely.

6. Use a quiet area with non-slip footing and no sharp objects.

7. Keep feed and water within easy reach, but do not force anything by mouth if swallowing is abnormal.

8. Do not give another medication unless instructed.

9. Monitor breathing, responsiveness and coordination continuously.

10. Prepare for referral if neurological support or prolonged recumbency management is required.

Do not attempt to “counteract” moxidectin with another dewormer, oil, charcoal, human medication or an unprescribed stimulant.

How Do You Know Whether Moxidectin Worked?

Use a faecal egg count reduction test.

A practical test involves:

1. Collecting faeces immediately before treatment

2. Treating the horses at the correct labelled dose

3. Collecting faeces from the same horses 14 days later

4. Comparing the reduction in strongyle egg output

5. Interpreting the results at group level

The AAEP recommends annual efficacy testing on each farm or barn. A group of at least five egg-positive horses is generally recommended, with larger groups providing more reliable results.

A treatment check from a single horse can provide useful clinical information, but it is less reliable for diagnosing resistance across an entire property.

Should You Check Again at Four to Eight Weeks?

This can be useful for ivermectin and moxidectin.

A 14-day result answers:

Did the product initially reduce egg shedding?

A later result answers:

How long did suppression last?

Current AAEP and CANTER guidance suggests that a practical egg reappearance spot-check may be performed at approximately four, six or eight weeks after treatment. This can identify unexpectedly early return of strongyle egg shedding.

The finding should not trigger automatic repeat dosing. It should trigger a review of the parasite-control programme.

What If the Faecal Egg Count Is Still High After Treatment?

Possible explanations include:

• Incorrect body-weight estimate

• Underdosing

• Product administered incorrectly

• Gel spat out

• Expired or poorly stored product

• Sample or laboratory error

• Testing at an unsuitable interval

• Parasite resistance

• A different parasite type from the one assumed

• Reinfection or shortened egg reappearance if testing was delayed

Confirm the practical details before declaring resistance.

Your veterinarian may recommend repeating the test under controlled conditions, testing additional horses or selecting a different effective drug class.

Common Mistakes Owners Make

Giving the Entire Syringe to Every Horse

A full US syringe treats up to 1,500 lb. That may be appropriate for a large horse but can be a major overdose for a pony or miniature horse.

Treating an Underweight Horse Without Investigation

The product label specifically warns against use in underweight or debilitated animals. Weight loss should be investigated rather than automatically blamed on worms.

Using QUEST in Foals Under Six Months

This is outside the current US label and creates an unnecessary toxicity risk.

Assuming QUEST Treats Tapeworms

Only the praziquantel-containing QUEST® PLUS formulation treats tapeworms.

Believing It Kills Every Encysted Larva

Moxidectin has valuable larvicidal activity, but it is not 100 percent effective.

Deworming Every Eight Weeks

Fixed year-round interval treatment accelerates resistance and is no longer recommended.

Rotating Products Blindly

Switching colours or brand names does not prevent resistance. Different brands may contain the same drug class.

Treating From a High Faecal Egg Count Alone

A high strongyle count identifies a high egg shedder. It does not directly measure the total intestinal burden or prove that parasites are causing illness.

Assuming a Zero Egg Count Means No Worms

Encysted larvae, male worms and immature stages do not contribute eggs to the sample.

Increasing Treatment Frequency When Eggs Reappear Early

Shortened egg suppression should lead to better testing and management, not simply more frequent moxidectin administration.

Repeating the Dose After the Horse Spits Some Out

Blind redosing can turn a partial treatment into an overdose.

Leaving Used Syringes Where Dogs Can Reach Them

Equine moxidectin products are highly concentrated. Product labels warn that exposure in other species, including dogs, can cause severe adverse reactions.

How Can You Reduce Dependence on Dewormers?

Medication is only one part of parasite control.

Remove manure regularly

Strongyle eggs are passed in manure and develop into infective larvae in the environment. Frequent manure removal reduces the number of larvae reaching pasture.

Avoid excessive stocking density

More horses on limited grazing generally means greater faecal contamination and exposure.

Do not spread uncomposted manure onto horse pasture

Spreading untreated horse manure can redistribute parasite eggs across the grazing area.

Proper composting generates heat that can destroy free-living parasite stages.

Protect feed from faecal contamination

Use feeders and avoid placing hay directly beside manure accumulation areas.

Monitor horses individually

A relatively small percentage of adult horses often contribute most of the strongyle egg output. Identifying these horses allows treatment to be focused rather than medicating the entire herd repeatedly.

Quarantine new arrivals

New horses can introduce resistant parasite populations. A quarantine parasite plan should consider previous treatment history, diagnostic testing, product efficacy and manure containment. Current CANTER guidance identifies quarantine as an important part of preventing movement of resistant worms between properties. (Canter Equine Resistance)

Record every treatment

Record:

• Horse

• Date

• Body weight

• Product

• Active ingredient

• Dose

• Batch number

• Reason for treatment

• Pre-treatment egg count

• Post-treatment result

• Any adverse effect

The colour of the box is not an adequate medical record.

Will My Horse Be Okay After QUEST?

A healthy horse that receives an accurately calculated labelled dose will usually tolerate treatment without a problem.

The outlook after an overdose depends on:

• The amount given

• The horse’s age

• Body weight

• Body condition

• Underlying illness

• Speed of veterinary intervention

• Severity of neurological signs

• Whether the horse remains standing and able to swallow

Published overdose cases include horses that recovered after several days of intensive supportive treatment. Severe and fatal toxicity has also been reported, particularly in young foals. (Mad Barn USA)

The safest strategy is prevention: weigh the horse, check the syringe twice and never assume the whole tube equals one horse.

Frequently Asked Questions

Is QUEST safer than ivermectin?

Both products are generally safe when used correctly, but they are not interchangeable. Moxidectin requires especially careful dosing in young, small, underweight or debilitated equids. The best product is the one that safely targets the relevant parasites and remains effective on the property.

How often can I give QUEST to my horse?

There is no appropriate universal interval. Current guidance advises against fixed year-round treatment. The timing should be based on regional transmission, horse age, previous treatment, faecal testing, efficacy and parasite risk.

Can I give QUEST to a miniature horse?

The product can be used in horses and ponies meeting the label requirements, but miniature horses require extremely accurate weight determination and dose setting. Seek veterinary guidance rather than guessing the dose.

Does QUEST treat bots?

The US label includes specified stages of Gasterophilus bots. However, AAEP guidance notes that moxidectin bot efficacy may be variable and that ivermectin may sometimes be the more effective bot treatment. Product selection should reflect the full parasite-control objective.

Does a low faecal egg count mean my horse does not need moxidectin?

Not necessarily. A low count indicates low egg shedding at that moment, but it does not detect encysted larvae. Whether larvicidal treatment is justified should be decided through a broader risk assessment rather than the egg count alone.

The Real Takeaway

QUEST® is a valuable dewormer, but it should not be treated as a routine tube to be given whenever the seasons change.

Moxidectin can control susceptible adult small strongyles and reduce certain encysted larval stages. It does not kill every larva, standard QUEST® does not treat tapeworms, and the historical 84-day egg-suppression claim may not reflect performance on every modern property.

Use it strategically. Confirm the horse is old enough and healthy enough. Obtain an accurate body weight. Give the labelled dose. Monitor product efficacy and do not respond to resistance by simply treating more often.

The aim is not the maximum number of deworming treatments. It is the minimum number of effective, well-timed treatments needed to protect the horse while preserving the few dewormer classes we still have.

---

Unsure whether moxidectin is appropriate for your horse, or trying to interpret faecal egg counts and previous treatment results? ASK A VET™ can help you organise the horse’s age, weight, grazing history, deworming record and test results so you can discuss a safer, evidence-based parasite-control plan with your veterinarian.